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Background: A tetravalent dengue vaccine demonstrated its protective efficacy in two phase III efficacy
studies. Results from these studies were used to derive vaccination impact in the five Asian (Indonesia,
Malaysia, Philippines, Thailand, Vietnam) and the five Latin American countries (Brazil, Colombia,
Honduras, Mexico and Puerto Rico) participating in these trials.
Methods: Vaccination impact was investigated with an age-structured, host-vector, serotype-specific
compartmental model. Parameters related to vaccine efficacy and levels of dengue transmission were
estimated using data collected during the phase III efficacy studies. Several vaccination programs, includ-
ing routine vaccination at different ages with and without large catch-up campaigns, were investigated.
Results: All vaccination programs explored translated into significant reductions in dengue cases at the
population level over the first 10 years following vaccine introduction and beyond. The most efficient
age for vaccination varied according to transmission intensity and 9 years was close to the most efficient
age across all settings. The combination of routine vaccination and large catch-up campaigns was found
to enable a rapid reduction of dengue burden after vaccine introduction.
Conclusion: Our analysis suggests that dengue vaccination can significantly reduce the public health
impact of dengue in countries where the disease is endemic.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Dengue is a mosquito-borne viral disease that has become an
increasing public health problem in tropical and subtropical
regions of the world [1–4]. Four viral serotypes of the Flavivirus
genus cause dengue disease in proportions that change unpre-
dictably over time, and from place to place, even within the same
country [5,6]. There is no specific treatment for dengue and current
vector control measures have in general failed to reduce the occur-
rence of dengue epidemics [7].
A recombinant yellow fever-17D–dengue virus, live, attenuated,
tetravalent dengue vaccine (CYD-TDV) has recently demonstrated
its efficacy against symptomatic, virologically-confirmed dengue
during the active surveillance phase (up to 25 months after the
first injection) of two phase III studies in 10 countries in Asia and
Latin America (Indonesia, Malaysia, Philippines, Thailand, Vietnam,and Brazil, Colombia, Honduras, Mexico, and Puerto Rico) [8,9].
During this period, vaccine efficacy rates against symptomatic den-
gue were 60.3% (95% confidence interval [CI], 55.7–64.5) for all par-
ticipants, 65.6% (95% CI, 60.7–69.9) for those aged 9 years or older
and 44.6% (95% CI, 31.6–55.0) for those younger than age 9 years
[10]. A long-term safety follow-up based on hospital surveillance
was undertaken beyond the active surveillance phase of these
two efficacy studies. The first results, corresponding to year 3 after
the first injection, indicated a 50% (95% CI, 0.29 to 0.86) reduction
in hospitalization for dengue among vaccinated participants aged
9 years or older. In contrast, an increase of 58% (95% CI, –0.17 to
2.02) was observed for those aged under 9 years. Based on this
information, five countries (Mexico, Brazil, Philippines, El Salvador,
Costa Rica) recently approved the use of CYD-TDV for individuals
aged 9–45 years living in endemic areas.
Following the completion of the active surveillance phase of the
two phase III studies, and the first registration of CYD-TDV, policy-
makers need evidence of the public health impact of vaccination to
inform decisions on vaccine introduction. In line with the World
Health Organization (WHO) recommendations, models of dengue
transmission can be used to address these important questions
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strategies [11]. Several mathematical models, including the one
used here [12], have been used to assess the population impact
of dengue vaccination before the final results of the CYD-TDV
phase III efficacy studies were available [13–19]. Nonetheless,
these modeling studies generally concluded that vaccination has
the potential to significantly reduce the burden of dengue.
We estimated in a companion paper [20] the key parameters of
our transmission model using the information collected during the
active surveillance of the two CYD-TDV phase III efficacy studies.
Here, our main objective was to assess the population impact of
dengue vaccination in the 10 countries participating in the phase
III efficacy studies. Since the publication of the companion paper,
data collected during the first year of the long-term safety
follow-up became available. We therefore revisited the estimation
of model parameters in the light of this additional data. We also
focused on vaccination programs targeting individuals aged
9 years or older for whom the vaccine is indicated.2. Methods
2.1. Model design
The mathematical model used in this analysis is an age-
structured, host-vector, serotype-specific compartmental model
that includes seasonality and accounts for the transmission dynam-
ics of the four dengue serotypes in human and mosquitoes at the
population level [12]. It can consider different types of serotype
interactions: temporary cross-protection (i.e. no risk of developing
a heterotypic infection for a limited time after an infection), cross-
enhancement (i.e. differential risk of developing symptomatic cases
upon primary, secondary, tertiary and quaternary infection), or a
combination of cross-protection and cross-enhancement.
Some modifications have been incorporated into the model
since it was first published. Following on from the work of
Rodriguez-Barraquer et al. [21], we simplified the representation
of cross-enhancement. We also modified the representation of vac-
cine protection by allowing a complete loss of vaccine protection
over time, a decrease in severity for breakthrough cases, and a level
of vaccine protection dependent on the number of previous dengue
infections. We also accounted for possible differences between the
efficacy against symptomatic and asymptomatic infections and did
not account for natural boosting of vaccine-derived immunity. In
line with the previous version of the model, we considered a ‘‘leaky
type” vaccine [22], i.e. each vaccinee retains a residual risk of infec-Table 1
Expansion factors (ratio between incidence of virologically-confirmed dengue and suspect
reproduction numbersb for the ten countries participating in the phase III efficacy trials.
Expansion factorsc Basic reproduction numbers (R0)
Dengue 1 Dengu
Median [95% CI] Median [95% CI] Media
Thailand 6.2 [4.6;8] 3.4 [3;3.9] 4.9 [4.
Colombia 10.3 [9.3;11.9] 4.3 [3.8;4.7] 2.9 [2.
Philippines 13.8 [11.5;16.5] 3.8 [3.5;4.1] 3.1 [2.
Brazil 1.8 [1.5;2.2] 2.7 [2.3;3.1] 3 [2.6;
Honduras 265.2 [207.6;322.6] 2.4 [2.1;2.6] 3.4 [3;
Indonesia 12.3 [9.6;15.5] 2.9 [2.5;3.3] 3.4 [3;
Vietnam 10.1 [8.1;13] 2.7 [2.4;3.1] 3 [2.6;
Puerto Rico 10.7 [4.9;16.2] 2.4 [2.3;2.6] 2.7 [2.
Mexico 10.9 [8.1;13.9] 2.4 [2.2;2.6] 2.5 [2.
Malaysia 14.3 [7.2;22.6] 2.1 [1.8;2.5] 2.3 [2;
a For periods, areas and age groups corresponding to the population of phase III studi
b Derived from the estimation performed on CYD-TDV phase III efficacy studies.
c Based on Scenario CPA.
d Derived from the average R0 over the 4 serotypes.tion in case of exposure. This assumption can be seen as conserva-
tive since, contrary to the alternative assumption (‘‘all-or-nothing”,
i.e. where a subset of individuals are fully protected against the
disease), it accounts for possible vaccine failure following repeated
exposure. The set of equations defining the model is detailed in
Supplementary information S1 (section S1.1).
Another difference from the previous model is the relative con-
tributions of symptomatic and asymptomatic infections to disease
transmission. Using available literature on the level of viremia gen-
erated by symptomatic and asymptomatic infections, and the level
required for virus transmission [23–27], we considered that both
contribute to disease transmission but with a higher risk for symp-
tomatic infection to generate a subsequent mosquito infection (rel-
ative risk set to four).
As with any transmission model, our model allows considera-
tion of both direct protection to vaccinees and indirect protection
for the entire population related to reduced disease transmission
due to vaccination. More complete information on the mechanisms
of indirect protection and the evidence used for its assessment can
be found in supplementary information S1 (section S1.3).
2.2. Model calibration
The main source of information for the calibration was derived
from the estimation performed with data collected during the two
CYD-TDV phase III studies [8,9]. We presented in the companion
paper [20] the results of the estimation performed on data col-
lected during the active surveillance phase (up to 25 months after
the first injection). Here, we revisited this estimation to account for
data collected during the first year of the long term safety follow-
up. This new estimation is presented in supplementary informa-
tion S1 (section S1.5) and was used for the assessment of the
serotype-specific basic reproduction numbers (Table 1).
To move from data collected among children and adolescents
(aged 2–14 years for Asian countries and 9–16 years for Latin
American countries) to a population-based analysis, we comple-
mented the phase III data with demographic information and rou-
tine surveillance data for the 10 countries included in the analysis.
To account for differences between the dengue incidence observed
during the trials, based on very active surveillance, and the inci-
dence of suspected dengue reported through passive surveillance
systems [28], we calculated country-specific expansion factors.
These expansion factors (Table 1) were based on the ratio between
the two incidences for the same age group, same area and same
period of time and were used to correct routine surveillance data
in all age groups.ed dengue cases during phase III trials and reported incidencea) and estimated basic
e 2 Dengue 3 Dengue 4 Rankd
n [95% CI] Median [95% CI] Median [95% CI]
3;5.6] 2.8 [2.5;3.1] 2.4 [2.1;2.7] 0
6;3.3] 3.4 [3.1;3.8] 2 [1.7;2.2] 1
8;3.4] 2.2 [2;2.4] 2.4 [2.1;2.6] 2
3.5] 3.3 [2.8;3.8] 2.1 [2.1;2.2] 3
3.8] 3.2 [3;3.4] 1.9 [1.7;2.1] 4
3.9] 2.5 [2.2;2.7] 2.1 [1.8;2.4] 5
3.4] 2 [1.8;2.3] 2.7 [2.5;3] 6
3;3] 2.2 [2;2.5] 1.2 [1.2;1.3] 7
4;2.7] 1.9 [1.7;2] 1.3 [1.2;1.3] 8
2.7] 1.8 [1.6;2] 1.8 [1.6;2.1] 9
es.
Table 2
Characteristics of the scenario considered for vaccine efficacy and interactions
between serotypes.
Scenario CPA
Interaction between serotypesa Temporary cross-protection & cross-
enhancement
Efficacy against symptomatic casesa
Efficacy per serotype Serotype-specific
Efficacy according to dengue status Lower for dengue naïve subjects
Efficacy against hospitalizations Higher efficacy against hospitalized
cases
Increase in efficacy with doses Increase in efficacy with doses for naïve
subjects
Annual waning rate for subjects
aged 9 years or older
Naïve subjects: 129.2% [90–311]
Pre-exposed subjects: 5.5% [2–10]
Vaccine-induced cross-
enhancement
Accelerated exposure to secondary
infectionb
Efficacy against asymptomatic
infection
50% [0–100] of the efficacy estimated
for symptomatic cases
a Estimated from data collected during the phase III efficacy trials.
b Vaccination plays a role similar to natural infection and exposes naïve subjects
to the same level of risk associated with a second dengue infection and pre-exposed
to the same level of risk associated to post-second dengue infections.
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reported age distribution of dengue cases. This comparison high-
lighted similar trends across countries; the reported incidence
was lower than that predicted in younger children but higher than
that predicted in older children. This result is consistent with pub-
lications reporting age-specific differences in the clinical features
of dengue [29–31] and the probability of developing symptomatic
infection [32,33], which reflects age-specific differences not
directly captured by the estimation performed on the data from
the specific age groups. Since age distribution of cases is an impor-
tant dimension in the burden of dengue, we accounted for these
differences by considering age-specific differences in expansion
factors. All impact result presented therefore account for the age
distribution of cases provided by country-specific surveillance sys-
tems while being corrected for under-reporting. More complete
information on the calibration procedure can be found in section
S1–6 of Supplementary information S1.
2.3. Scenarios of vaccine efficacy
The estimation performed on data collected during the active
surveillance phase of the two CYD-TDV phase III efficacy studies
presented in a companion paper [20] led to the identification of
vaccine efficacy scenarios accounting for differences in efficacy
by serotype, by severity, according to the number of previous
infections, and an increase in efficacy for vaccinated subjects never
exposed to dengue infections (seronegative or naïve subjects). We
also considered differences in the annual waning rate (exponential
decay) for subjects vaccinated when seronegative or seropositive.
Since the publication of this companion paper, data collected
during the first year of the long-term safety follow-up indicated
contrasting evolution of cases according to age [10]. Guy and Jack-
son [34] identified three interconnected hypotheses likely to
explain these results. Two of these hypotheses are included in
one of the scenarios identified in [20] (Scenario CPE): differences
in waning according to serological status at baseline and acceler-
ated exposure to a second dengue infection. The underlying
assumption behind accelerated exposure to a secondary dengue
infection is that vaccination acts as a primary natural infection
and exposes seronegative subjects directly to the same level of risk
of the infection becoming symptomatic corresponding to a second
dengue infection. Similarly, individuals exposed to at least one
dengue infection prior to vaccination (seropositive or pre-
exposed subjects) become exposed to the same level of risk of
infection becoming symptomatic associated with post-second
infection (i.e. second to third, and third to fourth). A similar
assumption was explored by Rodriquez-Barraquer et al. [14]. A
more detailed presentation of this mechanism can be found in sec-
tion S1–4 of Supplementary information S1.
Guy and Jackson [34] also identified a third hypothesis inter-
connected to the two former ones, and likely to explain observa-
tions made during the first year of long-term safety surveillance:
an age-specific mechanism independent from seropositivity. Here,
we revisited the estimation of model parameters to account for
data collected during the first year of the long-term safety surveil-
lance. We used scenario CPE but also explored additional scenarios
including age-specific mechanisms independent from seropositiv-
ity. The best fit was obtained for scenario CPA that accounts for
the three hypotheses considered by Guy and Jackson [34]. The
characteristics of scenario CPA, used to assess the impact of vacci-
nation presented here, are summarized in Table 2. Detailed results
of the estimation combining data collected during the active phase
and the first year of long-term safety surveillance can be found in
section S1–5 of supplementary information S1.
The estimation performed did not provide direct information on
the efficacy against asymptomatic infections. For this part, we usedthe results of an analysis performed on immunological data col-
lected during the two CYD-TDV phase III efficacy studies showing
a positive but lower efficacy than the one observed against symp-
tomatic cases [35]. This led us to consider, in the base case, an effi-
cacy against asymptomatic infection equal to 50% of the one
observed against symptomatic cases.2.4. Vaccination strategies
The impact of vaccination was simulated at the population level
through a comparison of the number of total dengue cases and
hospitalized dengue cases expected to occur with and without vac-
cination over a given period of time (from 5 to 50 years). In accor-
dance with phase III trials [8,9], we considered the tetravalent
vaccine administered in a three dose, 0–6–12 month regimen.
Strategies explored included routine vaccination at different
ages with a catch-up program corresponding to a mass vaccination
campaign at the beginning of the vaccination program targeting
people not eligible for routine vaccination. Once initiated, routine
vaccination occurs on a daily basis throughout the entire period
considered in the analysis. All individuals eligible for a catch-up
campaign receive the first dose during the first year of the vaccina-
tion program. These campaigns target individuals just too old for
routine vaccination, e.g., a catch-up campaign including four age
cohorts complementing routine vaccination at age 9 years will tar-
get children aged between 9 and 12 years on the day before the ini-
tiation of the vaccination program. Except where specifically
stated, we used for all vaccination programs, a coverage rate set
at 90%, i.e. vaccination each year of 90% of children reaching the
age targeted for routine vaccination and, in case of catch-up cam-
paign, vaccination of 90% of individuals who, at the time of vaccine
introduction, belonged to the targeted age group for this campaign.
For all strategies considered, we assumed no changes in vector
control activities once the vaccine is introduced.2.5. Sensitivity analyses
All impact results presented in this paper are based on multiple
simulations. We used 100 Monte Carlo simulations and presented
the median values as well as 95% confidence intervals. For each of
these simulations we used the posterior distribution of the esti-
mated vaccine efficacy parameters.We also varied the level of trans-
mission intensity in the range observed in each country for
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ent starting points for the introduction of the vaccine (with a 10 year
reference period). Finally, we used a uniform distribution for the rel-
ative efficacy against asymptomatic infections (0–100% of the effi-
cacy against ambulatory cases). The impact of vaccination was
measured using, for each simulation, the same set of parameters
with and without vaccination. Sensitivity analyses also included
specific analyses focused on the impact of efficacy against asymp-
tomatic infections, coverage rates, duration of protection and the
contribution of indirect protection to vaccination impact. The
method used for identifying the specific contribution of indirect pro-
tection is detailed in sections S1–3 of supplementary information S1.
3. Results
The main results of the analysis performed on the potential
impact of dengue vaccination at the population level are summa-
rized in Figs. 1–5. They are supported by a more extensive set of
results presented successively for each of the 10 countries in Sup-
plementary information S2.
3.1. Simulated evolution of dengue incidence in the absence of
vaccination
The simulated evolution of dengue incidence is characterized by
important year-to-year variations in rates and changes in domi-
nant serotype over time. The results for the Philippines are pre-
sented in Fig. 1a and in Supplementary information S2 for all 10Fig. 1. Selected results for the Philippines. (a) Simulated evolution of dengue incidence i
in 2016. (b) Prevented cases through direct and indirect protection over 10 years. (c) Prev
(d) Prevented cases over 10 years for different vaccinations programs over 10 years. Vacc
and 20 catch-up cohorts (Vaccination coverage: 90%).countries. No clear cyclic patterns were visible for the 40-year per-
iod considered in the simulations. The simulated incidences were
characterized either by frequent changes in annual dengue inci-
dence (e.g. Thailand, Honduras, Philippines) or periods of stable
incidence followed or preceded by a period of higher incidence
(e.g. Malaysia, Mexico). Whatever the country considered, second
and subsequent dengue infections accounted for the majority of
infections in those aged 9 years or older (from 75% in Mexico to
95% in Thailand).
3.2. Routine vaccination impact at different ages
We considered the potential impact of routine vaccination pro-
grams targeting children or adults aged 5–29 years. The median
cumulative reductions obtained for these vaccination programs
over a 20-year period in all countries are presented in Fig. 2. All
strategies tested resulted in a reduction of the dengue burden.
According to country, the largest reductions ranged from 21%
(Indonesia) to 29% (Mexico) for all dengue cases, and from 24%
(Indonesia) to 31% (Honduras) for dengue hospitalizations. In most
countries, the largest reduction in dengue burden was observed at
age 9 years, the only exceptions were Honduras, Malaysia
(13 years) and Mexico (17 years) for dengue hospitalizations.
3.3. Combination of routine and catch-up vaccination
We compared the potential impact over 10 years of catch-up
vaccination campaigns of different magnitudes complementingn the absence of vaccination and after the implementation of a vaccination program
ented cases at different periods after the implementation of a vaccination program.
ination program considered in (a) and (b) includes routine vaccination at age 9 years
Fig. 2. Cumulative reduction of dengue cases and dengue hospitalizations over 20 years in the population for routine vaccination programs only implemented at different
ages (R2: routine at age 2 years, NV: no vaccination) for Latin American countries (a and b), and Asian countries (c and d). Vaccination coverage: 90%, median reduction
derived from the results of the probabilistic sensitivity analysis. Number associated with each country corresponds to their endemicity rank (see Table 1).
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ered, broader catch-up campaigns were always associated with lar-
ger reductions in dengue cases and hospitalizations. For a program
including 20 catch-up cohorts, the reductions in hospitalizations
ranged from 45% (Thailand) to 68% (Honduras).
The number of dengue cases prevented by vaccine dose admin-
istered indicates that catch-up campaigns of adequate size are
likely to improve the efficiency of the program. In most cases, this
indicator peaks for programs including four to eight catch-up
cohorts (Fig. 3). The more complete analysis that can be found in
Supplementary information S2, nevertheless, indicates moderate
changes in the number of cases prevented per vaccine dose across
strategies (the range of variation of this indicator never exceeded
20%).
Contrary to routine vaccination, the largest reductions in dengue
cases and hospitalizations with catch-up vaccination were observed
for countries with the lowest transmission intensity (e.g.Malaysia in
Asia; Mexico and Puerto Rico in Latin America). Moving from 16 to
20 cohorts was still associated with significant reductions in Malay-
sia (e.g. from 62% to 68% for hospitalizations) whereas the additional
gain was more limited in Thailand (43–45%).3.4. Vaccination impact on hospitalization
Results reported in Fig. 3b highlight that whatever the country
and scenario considered, the reduction of hospitalized cases was
always slightly larger than the reduction against all dengue cases(median percentage of reduction 1–4 points higher over a 10 year
timescale).3.5. Impact of routine and catch-up vaccination over time
The implementation of a vaccination program does not stop the
year-to-year variations in dengue incidence but rather limits the
frequency and intensity of these variations. In the example shown
in Fig. 1a, once the vaccination is introduced the annual incidence
goes above 1.5% for only 3 years between 2016 and 2050 versus
9 years in the absence of vaccination. Similarly, the highest annual
dengue incidence after the implementation of the vaccination pro-
gram was lower than that with no vaccination (1.5% versus 2.0%,
respectively).
The impact of routine vaccination increased initially but pla-
teaued thereafter. For example, in the Philippines (Fig. 1c), the
reduction in dengue cases with routine vaccination reached 22%,
25% and 26%, respectively, during the first 5 years, 6–10 years
and 11–20 years after vaccine introduction. Compared to routine
vaccination only, the additional benefits generated by the catch-
up campaigns occur mainly during the first 10 years and more
specifically the first 5 years (77% reduction of dengue cases during
the first 5 years for the largest program considered in Fig. 1c). The
results presented in Supplementary information S2 show similar
trends whatever the country. The median levels of reduction over
5 years for a program including routine and 20 catch-up cohorts
range from 51% in Indonesia to 81% in Mexico.
Fig. 3. Cumulative reduction of dengue cases and dengue hospitalizations over 10 years in the population according to the routine vaccination program with catch-up cohorts
implemented (R9: routine at age 9 years, +4C: routine at age 9 years with 4 catch-up cohorts [9–12 years old], NV: no vaccination) for Latin American countries (a and b), and
for Asian countries (c and d). Vaccination coverage: 90%, median reduction derived from the results of the probabilistic sensitivity analysis. Number associated with each
country corresponds to their endemicity rank (see Table 1) and yellow circle to the strategy associated with the largest number of cases prevented per vaccine dose
administered.
Fig. 4. Vaccination impact over 10 years for the first cohort of 9-year-old children receiving vaccination. (a) Children vaccinated when seronegative. (b) All vaccinated
children. The vaccination program considered is a routine vaccination program at age 9 years combined with a catch-up campaign for those aged 10–17 years (8 catch-up
cohorts). Vaccination coverage: 90%.
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The impact of broader vaccination coverage is illustrated for the
Philippines in Fig. 1d. Higher coverage leads systematically to bet-
ter impact, irrespective of the vaccination strategy (routine vacci-nation alone or in combination with a catch-up program
including eight or 20 age cohorts). Conversely, Fig. 1d highlights
that the additional benefit of a catch-up campaign can only be
observed with sufficient coverage rates. The reduction in dengue
cases associated with a program including routine and 20 catch-
Fig. 5. Cumulative reduction of dengue cases over 10 years in the Philippines
population for a routine vaccination program alone or in combination with 8 or 20
catch-up cohorts according to the duration of protection (same duration for all
vaccinated subjects). Vaccination coverage: 90%.
6432 L. Coudeville et al. / Vaccine 34 (2016) 6426–6435up cohorts, and a coverage rate of 30%, was for instance lower than
routine only with a 90% coverage rate (18% and 23%, respectively).
3.7. Indirect protection
The roles of direct and indirect protection can be shown by sim-
ulating the evolution of dengue taking into account or not the
reduced transmission generated by a vaccination program. The
results for the Philippines over 10 years for a program including
routine vaccination at age 9 years and 20 catch-up cohorts are pre-
sented in Fig. 1b. For this scenario, the majority of the reduction
was driven by direct protection (28% for direct protection versus
20% for indirect protection). However, the relative contributions
of direct and indirect protection were variable. Results reported
in Supplementary information S2 for all 10 countries indicate that,
for the same vaccination program as in Fig. 1b, 37–68% of the over-
all reduction of dengue cases with vaccination was related to indi-
rect protection. The importance of indirect protection is that it
benefits the entire population (for instance in Fig. 1b, the 38%
reduction of dengue cases for children younger than age 5 years
was entirely driven by indirect protection). The benefits of direct
protection are substantial but limited to the population targeted
for vaccination (55% for 10–20-year-old vaccinated adolescents in
Fig. 1b).
3.8. Vaccination benefits for naïve subjects
The vaccination benefits over 10 years for 9-year-old children
vaccinated before any dengue infection is presented Fig. 4a. In all
countries for these children, vaccination translated into a reduction
of dengue cases despite the lower protection conferred by vaccina-
tion and the potential of accelerated exposure to a second dengue
infection. This reduction, which results from a combination of
direct and indirect protection, ranges from 32% for Malaysia to
42% in Honduras. As expected the reduction was larger for all chil-
dren vaccinated at age 9 years, i.e. seronegative and seropositive
children. The results presented in Fig. 4b indicate reductions in
dengue cases ranging from 58% to 68%.
3.9. Duration of vaccine protection
To assess the specific impact of different durations of vaccine
protection, we explored vaccination impact over 10 years for speci-
fic values of the average duration of vaccine protection, ranging 5–
20 years (Fig. 5). For this analysis, we did not make any distinctionbetween the duration of protection for naïve and pre-exposed
subjects.
Overall, vaccination impact increases with the duration of pro-
tection, but remains significant even for a short duration of protec-
tion. For instance, the median cumulative reduction in dengue
cases over 10 years for a routine vaccination program at age
9 years is 27% if the average duration of protection was 20 years
compared to 23% if the duration was 5 years. For programs includ-
ing catch-up campaigns, the duration of protection has a slightly
more important effect on the level of vaccination impact achieved
over 10 years. For instance, for a program including routine and 8
catch-up cohorts, the median reduction was 44% for a 20-year
duration of protection and 37% for a 5-year duration (7 point differ-
ence between the two scenarios versus 4 points for routine only
programs).4. Discussion
In this paper, we explored the potential impact of various den-
gue vaccination strategies in 10 endemic countries. All strategies
considered translated into significant reductions in dengue cases
at the population level. Routine vaccination at age 9 years was
shown to generate reductions in dengue cases ranging from 21%
to 29% over 20 years. Complementing routine vaccination with a
catch-up campaign was also found to significantly improve vacci-
nation impact during the first 10 years following vaccine introduc-
tion. For instance, a program including routine vaccination at age
9 years and 8 catch-up cohorts could prevent, on average over
the 10 countries considered in our analysis, 46% of the total num-
ber of dengue cases in the population over 5 years. Such vaccina-
tion program would require the vaccination of about 20% of the
population within 5 years. The vaccination impact was also larger
when considering specifically the benefits for vaccinated individu-
als (58–68% over 10 years for 9-year-old children).
The implementation of a vaccination program was not found to
stop variation of dengue incidence over time but rather limited the
frequency and intensity of these variations. However, the combina-
tion of routine vaccination and large catch-up campaigns signifi-
cantly limited the risk of a high dengue incidence during the first
few years following vaccine introduction.
Our analysis also provides insights into the potential value of
vaccination at different ages. The most efficient age for vaccination
varies with the intensity of transmission. This age increases as the
transmission intensity decreases. This finding is a direct conse-
quence of the efficacy profile of the vaccine characterized by a bet-
ter protection for subjects already exposed to a first dengue
infection before their vaccination. Given this profile, it is optimal
to vaccinate between the first and the second infection. This ‘‘ideal”
period for vaccination occurs on average at older ages as the trans-
mission intensity decreases. However, in the 10 countries consid-
ered, age 9 years was generally close to the most efficient age at
the population level, i.e. it maximizes, in most settings, the number
of vaccinations performed between the first and second dengue
infection among vaccine recipients. This result fits well with the
age range for which the vaccine is intended for use and is in line
with the indication recently approved by the authorities of five
Asian and Latin American countries (individuals aged 9–45 years
living in endemic areas [36]).
Interestingly, no significant drop in vaccination impact over
time was observed for routine vaccination even though vaccination
tends to reduce the proportion of individuals exposed to dengue at
a given age. The 25–30% reduction of dengue cases generated by
vaccination in the mid- and long-termwas not found to sufficiently
alter the disease dynamics for a drop in vaccination impact to
occur.
L. Coudeville et al. / Vaccine 34 (2016) 6426–6435 6433Vaccination was also found to provide a positive impact for 9-
year-old children vaccinated before their first dengue infection,
i.e. seronegative at baseline and considered dengue-naive. Accord-
ing to country, the reduction of dengue risk ranged from 32% to
42% over 10 years. This reduction is clearly lower than the one
observed for the entire vaccinated group (from 60% to 68%) but
remains positive. The lower impact for naïve subjects is a conse-
quence of the lower vaccine protection and the mechanism of
accelerated exposure considered in scenario CPA. However, this
reduces the direct protection but not the potential indirect protec-
tion that naïve subjects benefit from as well as anyone else in the
population. The consideration of a stronger waning of vaccine
protection or a large enhancement in case of a second dengue
infection would result in a more negative impact for subjects vac-
cinated when seronegative for the 10-year period considered here.
In addition, the increase in risk, under a scenario of accelerated
exposure to secondary infection, is only temporary and disappears
for individuals facing at least two infections. In the setting consid-
ered here the lifetime probability to face at least two dengue infec-
tions is very high (>99%). Therefore, the long-term benefit of
vaccination in naïve individuals is expected in any case to remain
positive.
Catch-up campaigns are of clear value in all countries to obtain
a rapid and significant reduction in dengue cases, but their impact
also depends on transmission intensity. The largest reductions
were observed in the countries with the lowest transmission inten-
sity such as Mexico or Malaysia. This result is related to the ability
of the vaccine to reduce transmission through indirect protection
in case of lower transmission intensity. It is also a consequence
of the vaccine efficacy profile i.e. increase in the optimal age for
vaccination as the transmission intensity decreases. In lower trans-
mission intensity settings, the catch-up campaigns considered
(from age 10 years) are more efficient in targeting directly age
groups in which the vaccination benefits are the largest.
Additional benefits generated by catch-up campaigns are also
visible during the first 5 years following their implementation
but not after 10 years. Interestingly, this absence of difference after
10 years compared to routine vaccination only indicates that the
additional benefits generated by catch-up campaigns are limited
in time but definitely acquired. However, we limited our analysis
to routine vaccination programs complemented by catch-up cam-
paigns implemented at the time of vaccine introduction. Additional
vaccination programs (e.g. booster vaccination, mass vaccination
programs implemented several years after vaccine introduction)
are likely to modify the evolution of vaccination impact over time.
It should be noted that, to ease comparisons, we considered the
same vaccination programs whatever the country and did not
account for all programmatic constraints (e.g. the ability to reach
the same vaccination coverage rate for different programs). The
differences in the impact of catch-up campaigns according to coun-
try, however, highlights the value of adapting catch-up programs
to the endemic setting considered. At this level, two additional
findings are of interest when performing more comprehensive
setting-specific analyses than the one presented here. First, we
found that the efficiency of a vaccination program, measured
through the number of dengue cases prevented per dose adminis-
tered, improves for a catch-up program of adequate size. The dif-
ference in efficiency remains, however, limited for vaccination
programs of different magnitude. Second, the analysis on vaccina-
tion coverage rates showed the value of high coverage rates over
extensive programs associated with low coverages.
We observed that the percentage reduction generated by a vac-
cination program is slightly larger for hospitalized dengue than all
symptomatic dengue cases. This better impact is a consequence of
the higher efficacy of the vaccine against hospitalized dengue.
However, the difference in impact remains lower than differencesin efficacy observed during phase III trials [8,9]. This stems from a
combination of direct protection (higher for hospitalized cases)
and indirect protection (similar for hospitalized and non-
hospitalized cases).
The contribution of indirect protection in the reduction of den-
gue burden generated by vaccination varies according to the epi-
demiologic setting, the vaccination program and the period of
time considered, but is always significant. However, when assess-
ing indirect protection, in contrast to other modeling analyses [13–
19], we did not assume similar but considered reduced efficacy
against asymptomatic compared to symptomatic infections [35].
One interesting aspect of indirect protection is that it provides a
way for the entire population to benefit from a vaccination pro-
gram and not just those eligible for vaccination.
The consideration of indirect protection is critical for an ade-
quate evaluation of population impact of a vaccination program.
Its contribution is, however, a subject of particular attention since,
contrary to direct protection, its direct assessment is generally per-
formed in post-licensure studies through specific study designs
[37]. Such studies are available for a number of vaccine-
preventable diseases [38–45] and all conclude on the importance
of indirect protection. Even if planned, such studies are not yet
available for dengue and we attempted here to make the best
use of available evidence.
We presented in the companion paper [20] the results and
methods used for estimating model parameters from data col-
lected during the active surveillance phase of CYD-TDV efficacy
studies. Here, we revisited the estimation performed to account
for data collected during the first year of the long-term safety
follow-up. The scenario that best simulated the observed data
identified allowed us to better reproduce differences observed
among age groups both during the active phase and the long-
term follow-up and notably the imbalance observed during the
first year of long-term safety surveillance in the 2–5-year-old pop-
ulation. Compared to the scenarios identified in [20], the main dif-
ference related to the consideration of an age-specific difference in
efficacy not related to the serological status of individuals before
vaccination. Such difference have been reported previously [10],
with a marked difference in efficacy between seronegative subjects
aged 9 years and above (52.5%; CI: 5.9–76.1) and those aged under
9 years (14.4%; CI: 111 to 63.5). The scenario used for the impact
results presented here account for three hypothesis proposed by
Guy and Jackson [34] to explain the results observed during the
first year of the long-term follow-up i.e. stronger waning of vaccine
protection for naïve subjects, accelerated exposure to a second
dengue infection in case of vaccination and age-specific mecha-
nisms independent of seropositivity.
Even if the model used was able to reproduce data observed
during the two efficacy studies, caution should be exercised when
extrapolating the conclusions we derived to settings different from
those considered here, notably to settings characterized by very
low transmission intensity and seropositivity rates in adolescent
and adult populations. Such settings are characterized by a lower
probability of acquiring two dengue infections which, according
to the scenario identified here, impacts the long-term benefits of
vaccination for seronegative subjects.
From a broader perspective, the uncertainties inherent to mod-
eling analyses like ours, based on a broad range of information of
varying robustness, should not be underestimated [46]. Although
we accounted for the two main aspects of interactions between
serotypes (cross-protection and cross-enhancement) identified in
the literature, we did not consider the whole range of possible rep-
resentations of dengue dynamics [11]. The vaccine mode of action
considered, even if it provides a plausible explanation of observa-
tions made during the trial, is also partly based on assumptions
not directly supported by observed data. In any case, it will there-
6434 L. Coudeville et al. / Vaccine 34 (2016) 6426–6435fore be important to revisit the analysis presented here as more
information from the long-term safety surveillance or post-
licensure studies become available.
Our conclusion that vaccination has the potential to signifi-
cantly impact dengue burden is, however, consistent with previous
analyses on the topic [13–19]. Moreover, some of these conclusions
were obtained using representations of dengue dynamics different
from those considered in our analysis (e.g. no third and fourth den-
gue infections [14], agent-based approach [13]).
An additional finding in our analysis was related to age-specific
differences in the probability of symptomatic disease upon infec-
tion not directly related to the higher symptomaticity of second
dengue infections. Such differences were already noted in previous
publications [32,33] and proved to be critical for reconciling data
collected during the trials with the various age distributions of
dengue cases obtained from routine surveillance. We also con-
firmed a level of under-reporting in routine surveillance systems
[28]. However, the objective here was not to precisely assess the
level of under-reporting in each country. This has been analyzed
in more detail in another publication through the consideration
of differences in the level of reporting of ambulatory and hospital-
ized cases [28].
5. Conclusion
The World Health Organization recommends the use of mathe-
matical models to inform decisions on vaccine introduction [11].
Our analysis contributes to this effort. Routine vaccination from
age 9 years was found to have a significant impact on dengue cases
across all settings explored. The combination of routine vaccina-
tion and catch-up campaigns provide an opportunity for a more
rapid reduction in the dengue burden compared with routine vac-
cination alone. The reduction in the burden of dengue at the pop-
ulation level was obtained for scenarios of vaccine efficacy
including the possibility of vaccine-induced cross-enhancement.
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